Synageva BioPharma Corp. is recruiting patients to participate in global clinical trials that evaluate sebelipase alfa (SBC-102) as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency. For more information, please visit, or click here if you would like to contact Synageva regarding LAL Deficiency.

Why Synageva

Synageva BioPharma Corp. is a biopharmaceutical company dedicated to discovering, developing and delivering therapies for patients with rare conditions and unmet medical need.


Everyone at Synageva shares a passion and commitment to improving the lives of patients with rare diseases. Our team is drawn from leading biotech companies that have helped bring several life saving therapies to patients whose diseases were once considered too rare for developing treatments. We believe that every patient deserves treatment options, regardless of the rarity of their disease.


We have established a culture that supports professional and personal growth for dynamic individuals with the work ethic, dedication, tenacity, integrity, commitment to excellence and passion to make a difference by improving the lives of patients with rare disease and supporting a work environment of mutual respect and trust.